Ignite Creation Date:
2024-05-06 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05341583
Status:
RECRUITING
Last Update Posted:
2023-07-14
First Post:
2022-04-18
Brief Title:
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase ALK Positive Non-small Cell Lung Cancer
Sponsor:
Betta Pharmaceuticals Co Ltd
Organization:
Betta Pharmaceuticals Co Ltd
Organization Data
Organization:
Betta Pharmaceuticals Co Ltd
Class:
INDUSTRY
Study ID:
BTP-42338
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Betta Pharmaceuticals Co Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None